Q2 2023

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • SELECT results show semaglutide 2.4 mg significantly reduces major adverse cardiovascular events
  • Novo Nordisk continues investments to expand production capacity
  • NEW FRONTIERS: Gene-editing partnership takes aim at hard-to-treat genetic disorders
  • Novo Nordisk launches world’s first cross-industry solution for recycling injection pens
  • Novo Nordisk to undertake 1:2 share split

 

Q1 2023

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • Novo Nordisk raises sales and operating profit outlook for 2023
  • A century of innovation, research and dedication
  • Novo Nordisk announces lower insulin pricing in the US, effective from January 2024
  • Oral semaglutide 25 mg and 50 mg show promise in phase 3 trial

Q3 2022

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes
  • Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and other rare blood disorders
  • Novo Nordisk partners with Microsoft to accelerate drug discovery and development using big data and artificial intelligence
  • Saxenda® obesity sales at an all-time high
     

Q2 2022

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • Novo Nordisk invests in expansion of production capacity to meet growing patient demand
  • A work of ‘smart’: Dialoq® launch brings digital connectivity to pre-filled insulin pens
  • Driving change in diabetes, one pedal stroke at a time
  • One step closer to bringing the world’s first once-weekly insulin treatment to patients


Q1 2022

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • Our response to the war in Ukraine
  • Taking obesity treatment to the next level
  • Strengthening the pipeline in rare disease
  • Harnessing the power of disruptive research technologies to develop next-generation treatments

Q3 2021

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • Key milestone reached in fight to ensure no child dies from diabetes
  • Production ramped up as initial demand for Wegovy in the US exceeds supply
  • ASCVD: Taking aim at one of the world’s biggest killers
  • Towards zero environmental impact: 15% reduction in CO2 emissions from suppliers

 


Q2 2021

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • New stem cell partnership targets chronic heart failure
  • Ozempic® approved in China
  • Novo Nordisk teams up with the University of Toronto to kickstart a new era in preventive public health
  • Stepping up the game in obesity treatment: WegovyTM approved in the US

 

Q1 2021

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • R&D organisation evolves into two areas
  • Oral semaglutide set to enter phase 3 development for Alzheimer’s disease
  • Digital health: first smart pens launched in Sweden
  • Rybelsus® launched in Japan – one of the world’s largest oral anti-diabetes markets

Q3 2020

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • Phase 2 trial successfully completed with ziltivekimab
  • Raised 2020 outlook on 8 October 2020
  • Not if, but how: new strategy steps up our efforts to Defeat Diabetes
  • 100% renewable power target for direct suppliers launched in 2020
  • 100 years ‎young: why we’re investing in the future of insulin
     

Q2 2020

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • Clinical results support Strategic Aspiration for obesity treatment
  • Novo Nordisk acquires Corvidia Therapeutics and expands presence in cardiovascular disease
  • Lose or reuse? How we are repurposing our insulin pens
  • A deep dive into NASH and Novo Nordisk’s activities in tackling this disease
  • Highlights from the first six months of 2020
     

Q1 2020

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • An unprecedented challenge: our response to COVID-19
  • Rybelsus® approved in the EU
  • Obesity through the lens: the truth from within
  • Prevention or cure? When it comes to type 1 diabetes, we are working on both
  • Highlights from the first three months of 2020

Q3 2019

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • A new era in diabetes care: Rybelsus® approved in the USA
  • New affordability initiatives to be launched in the USA
  • People and purpose: Monique Carter on driving culture change at Novo Nordisk
  • Intensifying China’s fight against diabetes
  • Highlights from the first six months of 2019

 

Q2 2019

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • A new mindset for environmental responsibility
  • Obesity: The brain is the battleground
  • Outcomes trials: Can semaglutide go even further in addressing patient needs?
  • Maximising the growth potential
  • Listen and lead: Ludovic Helfgott on returning biopharm to growth
  • Highlights from the first six months of 2019

 

Q1 2019

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • Oral semaglutide filed in the US and EU
  • The day I fired my doctor
  • Safely in the Rainbow
  • Shaped tablet key to oral delivery of insulin
  • Novo Nordisk addresses affordable insulin
  • Accelerating growth in Latin America
  • Highlights from the first three months of 2019

 

Q3 2018

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Letter from the CEO, Lars Fruergaard Jørgensen
  • Highlights from the first nine months of 2018
  • Tresiba® revitalised with new ‘Hypos matter’ 
  • Novo Nordisk research centre opens in oxford
  • Connected insulin pens poised for launch

 

Q2 2018

SHARE Magazine UK | SHARE Magazine DK

Index

  • Letter from the CEO, Lars Fruergaard Jørgensen
  • Highlights from the first six months of 2018
  • Oral semaglutide shows promising results
  • Ozempic® heading for the European market
  • Novo Nordisk focuses on treating obesity
  • Red Cross and Novo Nordisk enters partnership

 

Q1 2018

SHARE Magazine UK

Index

  • Letter from the CEO, Lars Fruergaard Jørgensen
  • Highlights from the first three months of 2018
  • Oral semaglutide shows promising results
  • Ozempic® approved in the EU and Japan
  • First phase 3a trial with oral semaglutide completed
  • Updated Tresiba® label approved in the USA
  • How Novo Nordisk’s products in Cuba

Q3 2017

SHARE Magazine UK | SHARE Magazine DK

Index

  • Letter from the CEO, Lars Fruergaard Jørgensen
  • Highlights from the first nine months of 2017
  • Camilla Sylvest joins executive management
  • SUSTAIN 7: Semaglutide compared to dulaglutide
  • Victoza® CV label approved in the US and the EU
  • Fiasp® a fast-acting insulin approved in the US
  • Ambitious global goal: To prevent 100 million new cases of diabetes by 2045

 

Q2 2017

SHARE Magazine UK | SHARE Magazine DK

Index

  • Letter from the CEO, Lars Fruergaard Jørgensen
  • Highlights from the first six months of 2017
  • Label update for Tresiba® submitted in the US
  • A step closer towards a CV indication for Victoza®  
  • Phase 2 obesity data for semaglutide
  • New data on Xultophy® 
  • Why Novo Nordisk is helping refugees

 

Q1 2017

SHARE Magazine UK | SHARE Magazine DK

Index

  • Letter from the CEO, Lars Fruergaard Jørgensen
  • Highlights from the first three months of 2017
  • Doug Langa new head of North America Operations
  • Fiasp® launched in Canada and EU markets
  • New research centre in Oxford
  • CHMP endorses Refixia® 
  • World Diabetes Foundation 15 th anniversary

Investors

Share price

{{priceData.date}} {{priceData.time}}

{{priceData.currentPrice}} {{priceData.currency}}
Go to stock watch {{priceData.change}} {{priceData.currency}}

Annual Report

Cover page of the Novo Nordisk Annual Report 2022

Annual Report 2022

Download Annual Report